The Asia Pacific molecular point of care diagnostics market is projected to register a CAGR of 15.33% during the forecast period, 2019-2028. The increasing efforts by the countries of the region with respect to the adoption of precision medicine solutions, and the various initiatives undertaken for the promotion of research and development of the same so as to enhance patient health, are the dominant factors impacting the market growth in the region.

ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET FORECAST 2019-2028

Asia Pacific Molecular Point of Care Diagnostics Market by Technology (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, Other) by Product (Assays, Instruments, Software) by Application (Infectious Disease, Oncology, Prenatal, Others) by End-user (Hospitals, Clinics, Diagnostics Centres, Others) and by Geography.

Request free sample

Report Summary

To know more about this report, request a free sample copy

The countries analyzed in the Asia Pacific molecular point of care diagnostics market include, Indonesia, Thailand, South Korea, India, Australia & New Zealand, Japan, China, Vietnam, and the rest of Asia Pacific. In China, the aging population is on the increase, and subsequently, there has been a rise in chronic conditions like heart disease, diabetes, cancer, etc. This has led to immediate reforms in healthcare services. The country is also one of the leading contributors to the global in vitro diagnostics (IVD) market. One of the significant drivers of market growth is the initiatives taken by the government to make precision medicine approach a standard practice. The local players of the region are developing molecular diagnostics point of care with regard to infectious disease testing based on RT-PCR technology.

In India, the molecular point of care industry is in its nascent stage, restrained by an import-centric and fragmented structure. There has been an increase in the number of Indians with health insurance in the past few years. The government’s efforts in incorporating more number of citizens under health insurance for enhancing accessibility to advanced and effective targeted treatments will drastically increase the adoption of innovative diagnostic tools like molecular diagnostics point of care.

Luminex Corporation manufactures, develops, and provides proprietary molecular testing technologies for the pharmaceutical, life sciences, diagnostics industries across the world. The product portfolio includes Verigene System, Verigene Bloodstream infection test, Verigene II System, Verigene gastrointestinal infection tests, etc. The company has its presence in the Americas, Africa, the Asia Pacific, the Middle East, and Europe.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
MARKET DYNAMICS
- MARKET DEFINITION
- KEY DRIVERS
  - DEMAND FROM GOVERNMENTS FOR DIAGNOSING COVID-19 POSITIVE PATIENTS
  - RISE IN DEMAND FOR NON-INVASIVE DIAGNOSIS
  - GROWTH IN THE NUMBER OF DISEASES
  - FUNDING FOR RESEARCH AND DEVELOPMENT
  - TECHNOLOGICAL ADVANCEMENTS IN THE MARKET
- KEY RESTRAINTS
  - HIGH CAPITAL REQUIREMENT
  - LACK OF HIGH COMPLEXITY TESTING CENTERS

KEY ANALYTICS
- KEY INVESTMENT INSIGHTS
- PORTER’S FIVE FORCE ANALYSIS
  - BUYER POWER
  - SUPPLIER POWER
  - SUBSTITUTION
  - NEW ENTRANTS
  - INDUSTRY RIVALRY
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- REGULATORY FRAMEWORK
MARKET BY TECHNOLOGY
- POLYMERASE CHAIN REACTION
  - REAL TIME PCR
  - DIGITAL PCR
- ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
- OTHER
MARKET BY PRODUCT
- ASSAYS
- INSTRUMENTS
- SOFTWARE
MARKET BY APPLICATION
- INFECTIOUS DISEASE
  - RESPIRATORY
  - HOSPITAL ACQUIRED INFECTIONS
  - SEXUALLY TRANSMITTED INFECTIONS
  - GASTRO INTESTINAL INFECTIONS
- ONCOLOGY
- PRENATAL
- OTHERS
MARKET BY END-USER
- HOSPITALS
- CLINICS
- DIAGNOSTICS CENTRES
- OTHERS
GEOGRAPHICAL ANALYSIS
- ASIA PACIFIC
  - CHINA
  - JAPAN
  - INDIA
  - SOUTH KOREA
  - INDONESIA
  - THAILAND
  - VIETNAM
  - AUSTRALIA & NEW ZEALAND
  - REST OF ASIA PACIFIC

COMPANY PROFILES
- ABBOTT LABORATORIES
- ABACUS DIAGNOSTICA
- BIOMÉRIEUX SA
- BIOCARTIS NV
- DANAHER CORPORATION
- DIASORIN SPA
- BIO-RAD
- F HOFFMANN-LA ROCHE AG
- LUMINEX CORPORATION
- HOLOGIC INC
- MESA BIOTECH
- SPARTAN BIOSCIENCES INC
- QUANTUMDX GROUP LTD
- QUIDEL CORPORATION
- QIAGEN NV

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – MOLECULAR POINT OF CARE DIAGNOSTICS

TABLE 2: EMERGENCY USE AUTHORISATION FOR DIAGNOSTICS BY FDA

TABLE 3: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 4: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 5: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PCR TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 6: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PCR TECHNOLOGY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 7: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 8: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 9: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 10: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 11: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 12: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 13: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 14: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 15: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 16: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: KEY INVESTMENT INSIGHTS

FIGURE 2: PORTER’S FIVE FORCE ANALYSIS

FIGURE 3: VALUE PROPOSITION – LABORATORY, IMMUNOASSAY, AND MOLECULAR POC DIAGNOSTIC

FIGURE 4: OPPORTUNITY MATRIX

FIGURE 5: VENDOR LANDSCAPE

FIGURE 6: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2018

FIGURE 7: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)

FIGURE 8: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY PCR TECHNOLOGY, IN 2018

FIGURE 9: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY REAL TIME PCR, 2019-2028 (IN $ MILLION)

FIGURE 10: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIGITAL PCR, 2019-2028 (IN $ MILLION)

FIGURE 11: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, 2019-2028 (IN $ MILLION)

FIGURE 12: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHER, 2019-2028 (IN $ MILLION)

FIGURE 13: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2018

FIGURE 14: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ASSAYS, 2019-2028 (IN $ MILLION)

FIGURE 15: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INSTRUMENTS, 2019-2028 (IN $ MILLION)

FIGURE 16: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SOFTWARE, 2019-2028 (IN $ MILLION)

FIGURE 17: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2018

FIGURE 18: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)

FIGURE 19: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY INFECTIOUS DISEASE, IN 2018

FIGURE 20: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY RESPIRATORY, 2019-2028 (IN $ MILLION)

FIGURE 21: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL ACQUIRED INFECTIONS, 2019-2028 (IN $ MILLION)

FIGURE 22: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SEXUALLY TRANSMITTED INFECTIONS, 2019-2028 (IN $ MILLION)

FIGURE 23: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY GASTRO INTESTINAL INFECTIONS, 2019-2028 (IN $ MILLION)

FIGURE 24: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ONCOLOGY, 2019-2028 (IN $ MILLION)

FIGURE 25: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRENATAL, 2019-2028 (IN $ MILLION)

FIGURE 26: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)

FIGURE 27: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2018

FIGURE 28: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITALS, 2019-2028 (IN $ MILLION)

FIGURE 29: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY CLINICS, 2019-2028 (IN $ MILLION)

FIGURE 30: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIAGNOSTIC CENTRES, 2019-2028 (IN $ MILLION)

FIGURE 31: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)

FIGURE 32: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 33: CHINA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 34: JAPAN MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 35: INDIA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 36: SOUTH KOREA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 37: INDONESIA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 38: THAILAND MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 39: VIETNAM MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 40: AUSTRALIA & NEW ZEALAND MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 41: REST OF ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

Segmentation

GEOGRAPHICAL ANALYSIS
- ASIA PACIFIC
  - CHINA
  - JAPAN
  - INDIA
  - SOUTH KOREA
  - INDONESIA
  - THAILAND
  - VIETNAM
  - AUSTRALIA & NEW ZEALAND
  - REST OF ASIA PACIFIC

MARKET BY TECHNOLOGY
- POLYMERASE CHAIN REACTION
  - REAL TIME PCR
  - DIGITAL PCR
- ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
- OTHER
MARKET BY PRODUCT
- ASSAYS
- INSTRUMENTS
- SOFTWARE
MARKET BY APPLICATION
- INFECTIOUS DISEASE
  - RESPIRATORY
  - HOSPITAL ACQUIRED INFECTIONS
  - SEXUALLY TRANSMITTED INFECTIONS
  - GASTRO INTESTINAL INFECTIONS
- ONCOLOGY
- PRENATAL
- OTHERS
MARKET BY END-USER
- HOSPITALS
- CLINICS
- DIAGNOSTICS CENTRES
- OTHERS

Request Free Sample

To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.